A study further supporting rVAR2 as a potentially universal cancer targeting molecule published in Nature Communications

Today our researchers at Copenhagen University and University of British Columbia together with academic partners in United Kingdom, Australia and Taiwan published an article in Nature Communications that demonstrates that rVAR2 indeed can be used as a tool to capture and isolate circulating tumour cells (CTCs) of various types. This is an important event also for VAR2 Pharmaceuticals because the result is an additional piece of evidence for that rVAR2 could be an effective targeting molecule when treating various types of metastatic cancers.

The publication can be found here.

Visit VarCT Diagnostics website.